GleamWall
中文EN

RBOT Vicarious Surgical Inc.

Orthopedic, Prosthetic & Surgical Appliances & Supplies · OTC · SEC CIK 1812173 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-177.5%
ROA-115.0%
ROIC (approx.)-178.7%
Asset turnover—

Leverage & solvency

Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-31
Income statement
Revenue————————
R&D expense$7.14M$7.99M$9.05M$9.41M$8.46M$10.80M$10.92M$9.97M
SG&A expense$2.62M$3.16M$4.12M$5.29M$5.54M$5.75M$5.59M$5.00M
Operating income-$9.26M-$11.50M-$13.52M-$15.75M-$14.98M-$17.75M-$17.71M-$16.11M
Pretax income-$10.52M-$11.06M-$13.21M-$15.39M-$13.93M-$17.09M-$15.21M-$17.00M
Net income-$10.52M-$11.06M-$13.21M-$15.39M-$13.93M-$17.09M-$15.21M-$17.00M
EBITDA-$8.97M-$11.15M-$13.11M-$15.38M-$14.44M-$17.25M-$17.19M-$15.59M
EPS (basic)——————-2.59-0.10
EPS (diluted)——————-2.59-0.10
Weighted avg. shares (diluted)—5.95M5.94M5.92M—5.90M5.87M5.86M
Balance sheet
Cash & equivalents$2.57M$3.16M$3.91M$2.60M$9.74M$8.01M$21.19M$39.16M
Short-term investments$7.22M$10.25M$20.05M$34.76M$39.36M$53.80M$52.98M$45.90M
Current assets$11.58M$15.07M$26.07M$39.65M$51.70M$63.98M$75.93M$87.11M
PP&E, net$1.27M$3.48M$3.79M$4.11M$4.48M$4.82M$5.33M$5.89M
Total assets$19.58M$29.35M$40.89M$55.05M$67.72M$80.62M$93.35M$105.29M
Current liabilities$3.90M$3.18M$5.10M$7.86M$7.67M$8.60M$7.18M$5.08M
Total liabilities$9.74M$15.26M$17.83M$20.98M$21.02M$22.73M$21.49M$21.28M
Shareholders' equity$9.84M$14.09M$23.06M$34.08M$46.70M$57.88M$71.86M$84.01M
Cash flow statement
Operating cash flow-$9.31M-$10.46M-$13.53M-$11.77M-$11.79M-$12.69M-$11.02M-$14.46M
Capital expenditure——$0$5,000——$6,000$10,000
Free cash flow——-$13.53M-$11.77M——-$11.03M-$14.47M
Investing cash flow$3.02M$9.69M$14.82M$4.61M$14.45M-$492,000-$6.95M-$144,000
Financing cash flow$5.69M$26,000$24,000$17,000$6,000$0$0$2,000
Depreciation & amortization$291,000$352,000$413,000$369,000$542,000$507,000$524,000$521,000
Stock-based compensation$1.10M$2.05M$2.20M$2.79M$2.81M$2.94M$3.07M$3.09M

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.